Last updated: August 1, 2026
Theophylline and Dextrose 5% in a plastic container is a legacy intravenous theophylline product used primarily in hospital settings. Its commercial position is limited by the decline of theophylline in respiratory-care guidelines, competition from inhaled bronchodilators and corticosteroids, narrow therapeutic index, drug-interaction risk, and the availability of alternative parenteral therapies. No product-specific clinical-development program or meaningful modern patent estate supports market expansion. The product is best characterized as a mature, low-growth generic hospital injectable.
What is Theophylline and Dextrose 5% in Plastic Container?
The product is an intravenous solution containing theophylline in 5% dextrose, supplied in a flexible plastic infusion container. Theophylline is a methylxanthine bronchodilator. It produces bronchodilation through phosphodiesterase inhibition and adenosine-receptor antagonism, although its therapeutic window is narrow and exposure varies substantially between patients.
The product should be distinguished from aminophylline injection. Aminophylline is a theophylline-ethylenediamine complex, while the product discussed here contains theophylline directly. Dosing, concentration, compatibility, and prescribing information are not interchangeable without clinical review.
| Attribute |
Product profile |
| Active ingredient |
Theophylline |
| Delivery route |
Intravenous infusion |
| Diluent |
Dextrose 5% in water |
| Container |
Flexible plastic infusion container |
| Therapeutic class |
Methylxanthine bronchodilator |
| Main historical use |
Severe bronchospasm and obstructive airway disease |
| Regulatory category |
Prescription drug product |
| Biosimilar applicability |
None |
| Patent profile |
Legacy active ingredient with limited current exclusivity value |
| Commercial setting |
Institutional and hospital pharmacy |
FDA-approved labeling for parenteral theophylline products emphasizes individualized dosing, serum-concentration monitoring, infusion-rate control, and interaction management because toxicity can produce nausea, vomiting, tachyarrhythmia, hypotension, seizures, and other serious effects (U.S. Food and Drug Administration [FDA], n.d.-a).
What is the FDA regulatory status of Theophylline and Dextrose 5%?
The product category is regulated as an approved prescription injectable drug, but the status of a specific National Drug Code can vary by manufacturer, marketing status, and supply period. FDA approval of a theophylline-in-dextrose presentation does not establish that every historical NDC remains actively marketed.
The relevant regulatory questions are:
- Whether the specific NDC is listed as active in FDA databases.
- Whether the manufacturer continues commercial distribution.
- Whether the product has been discontinued or is temporarily unavailable.
- Whether the product is listed as therapeutically equivalent to another approved injectable presentation.
- Whether a particular container presentation has current labeling and manufacturing support.
For hospital procurement, the active NDC and current manufacturer supply status are more relevant than the existence of an older approval record.
Is the product in the FDA Orange Book?
The Orange Book primarily identifies approved drug products and patent or exclusivity information relevant to abbreviated new drug applications. A legacy theophylline injectable product may appear in FDA approval databases without having meaningful listed patents or current market exclusivity.
Theophylline was discovered and commercialized decades ago. Any composition-of-matter exclusivity has expired. Current commercial protection, if any, would have to arise from a later formulation, container, manufacturing, or use patent. No commercially significant modern patent position is generally associated with theophylline in 5% dextrose infusion products.
Are there clinical trials for Theophylline and Dextrose 5% in Plastic Container?
No active product-development program is apparent for the specific theophylline-and-dextrose plastic-container presentation. Clinical research involving theophylline has historically focused on asthma, chronic obstructive pulmonary disease, neonatal respiratory disorders, pharmacokinetics, and drug interactions rather than development of this specific containerized infusion product.
The clinical evidence base is therefore legacy evidence for theophylline and parenteral administration, not a contemporary trial program designed to expand the product label.
| Clinical-trial category |
Current relevance |
| Product-specific registration trials |
No meaningful active program identified |
| New indication trials |
Limited and not commercially material |
| Pharmacokinetic studies |
Historically important because of variable clearance |
| Safety studies |
Relevant to therapeutic-drug monitoring |
| Pediatric or neonatal studies |
Exists historically for theophylline, but does not create new product exclusivity |
| Comparative efficacy studies |
Mostly superseded by newer bronchodilator strategies |
ClinicalTrials.gov contains historical studies involving theophylline, but the presence of such studies does not establish approval, current development, or commercial momentum for the plastic-container product (National Library of Medicine, n.d.).
When does Theophylline lose exclusivity?
Theophylline lost active-ingredient exclusivity decades ago. The product is therefore exposed to generic competition and does not have a conventional branded-drug exclusivity runway.
| Exclusivity category |
Status |
| New chemical entity exclusivity |
Expired |
| Composition-of-matter patent |
Expired |
| Orphan-drug exclusivity |
Not applicable to the general product |
| Pediatric exclusivity |
No current commercial significance |
| New formulation exclusivity |
No broadly recognized, commercially material term |
| Method-of-use exclusivity |
No known current barrier to generic substitution |
| Biosimilar exclusivity |
Not applicable |
Any remaining protection would likely be narrow and presentation-specific. A plastic container, dextrose vehicle, concentration, or infusion configuration can be covered by a patent in some circumstances, but those rights generally do not recreate market exclusivity for an old active ingredient.
What patents protect Theophylline and Dextrose 5%?
The primary theophylline molecule is not patent-protected. Potential patent categories include:
- Container and closure systems.
- Flexible-bag materials and oxygen-barrier technology.
- Manufacturing processes for sterile filling.
- Stability-enhancing excipients.
- Specific concentration or infusion regimens.
- Combination methods involving respiratory disease treatment.
These categories are unlikely to prevent generic development unless a patent is both unexpired and broad enough to cover the marketed product. Manufacturing and container patents can usually be designed around or avoided through alternative packaging and process controls.
| Patent layer |
Commercial assessment |
| Theophylline active ingredient |
No meaningful live protection |
| Dextrose 5% vehicle |
No product-level exclusivity |
| Plastic infusion container |
Potentially technical, but narrow and design-around risk is high |
| Sterile manufacturing process |
May create operational know-how, not durable market exclusivity |
| Method of treatment |
Limited value where the use is established and generic labeling is available |
| Drug-device combination |
No broad exclusivity apparent for the product category |
The main intellectual-property barrier is therefore low. The more relevant barriers are sterile manufacturing capability, quality-system compliance, hospital contracting, supply reliability, and product economics.
How strong is the patent estate for this product?
The patent estate is weak from a pharmaceutical investment perspective. There is no apparent unexpired composition-of-matter right, no biosimilar-style regulatory barrier, and no recognized formulation platform that would support premium pricing.
Patent strength can be assessed across five factors:
| Factor |
Assessment |
| Breadth |
Low |
| Remaining term |
Minimal or none at the active-ingredient level |
| Enforceability |
Potentially relevant only to narrow process or packaging rights |
| Design-around risk |
High |
| Ability to delay generic entry |
Low |
A patent challenge would have limited strategic value unless it targeted a specific unexpired formulation or manufacturing patent. For most competitive purposes, the product should be analyzed as an off-patent injectable.
What is the market outlook for Theophylline and Dextrose 5%?
The market is mature, fragmented, and likely declining or flat in unit demand. Public market-research reports generally do not isolate sales of this exact NDC, container configuration, or concentration. Revenue projections must therefore be based on hospital-use trends and supplier participation rather than a separately reported global market series.
Demand drivers
Demand persists because:
- Some hospitals retain theophylline or aminophylline in respiratory-care formularies.
- The drug remains available for selected refractory bronchospasm cases.
- Institutional protocols may preserve legacy use.
- Generic injectable products can be inexpensive relative to newer branded therapies.
- Supply disruptions involving alternatives can temporarily support demand.
Demand constraints
The principal constraints are:
- Narrow therapeutic index.
- Need for serum-level monitoring.
- Frequent drug interactions.
- Variable hepatic clearance.
- Risk of arrhythmia and seizures.
- Reduced guideline preference in asthma and chronic obstructive pulmonary disease.
- Greater use of inhaled beta-agonists, anticholinergics, corticosteroids, and other acute-care therapies.
- Hospital pharmacy preference for products with predictable dosing and broad supplier availability.
| Market factor |
Direction |
| Underlying clinical demand |
Declining to stable |
| Unit pricing |
Low and competitive |
| Gross-margin potential |
Limited |
| Formulary retention |
Selective |
| Dependence on shortages |
Moderate |
| New-indication potential |
Low |
| Patent-supported pricing |
None |
| Long-term market growth |
Unlikely |
What is the projected market size and revenue opportunity?
A defensible product-specific market-size estimate is not available from public data because sales are not typically disclosed separately for theophylline in 5% dextrose plastic containers. The commercial opportunity is best modeled as a small institutional generic segment rather than a growth pharmaceutical market.
Base-case projection
| Period |
Expected market direction |
Commercial interpretation |
| Near term |
Flat to modest decline |
Continued use in selected hospitals |
| Three-year horizon |
Decline likely |
Lower utilization and formulary substitution |
| Five-year horizon |
Low-growth or declining |
Ongoing generic supply with episodic shortages |
| Upside case |
Temporary increase |
Competitor withdrawal or injectable shortages |
| Downside case |
Accelerated decline |
Product discontinuation or broad formulary replacement |
Revenue exposure is most relevant for manufacturers with a broader hospital-injectable portfolio. A standalone product strategy would have limited scale and would depend on low-cost sterile manufacturing, reliable procurement contracts, and supply continuity.
Which companies compete with Theophylline and Dextrose 5%?
Competition comes from two groups.
Direct pharmaceutical competitors
These include manufacturers of:
- Theophylline injection.
- Aminophylline injection.
- Other theophylline-containing parenteral products.
- Alternative concentrations or container sizes.
- Hospital-compounded or institutional pharmacy preparations where permitted.
The identity of active competitors changes because generic injectable products are frequently discontinued, transferred, or placed on shortage allocation.
Therapeutic competitors
The product competes clinically with:
- Nebulized albuterol.
- Nebulized ipratropium.
- Systemic corticosteroids.
- Intravenous magnesium sulfate in selected severe asthma cases.
- Other bronchodilator and respiratory-support protocols.
Therapeutic substitution is a larger commercial threat than patent-based generic entry. The product can lose demand even when no new theophylline competitor enters the market.
What generic entry risks exist?
Generic-entry risk is already realized because theophylline is an old, off-patent active ingredient. A new entrant would not face a branded patent cliff. The main entry barriers are operational:
- FDA-compliant sterile manufacturing.
- Container compatibility and stability validation.
- Extractables and leachables testing for plastic systems.
- Sterility assurance.
- Particulate-control requirements.
- Reliable supply of active pharmaceutical ingredient.
- Hospital contracting and wholesaler access.
- Commercially viable batch economics.
A new generic entrant could pressure price, but the small market may discourage entry unless an incumbent exits or a shortage develops.
What manufacturing and intellectual-property barriers matter?
The principal manufacturing risk is not synthesis of theophylline. It is production of a stable, sterile, injectable product in a flexible container.
Key technical controls include:
- Container-closure integrity.
- Compatibility between theophylline, dextrose, and plastic materials.
- Stability over the labeled shelf life.
- Control of particulate matter.
- Endotoxin and sterility specifications.
- Protection against container damage during shipping.
- Validation of infusion administration conditions.
These requirements can create meaningful operational barriers even when patent protection is absent. They do not usually produce durable pricing power because multiple sterile-injectable manufacturers can use alternative container platforms.
What patent litigation and Paragraph IV challenges affect the product?
No material contemporary patent-litigation trend is associated with theophylline and dextrose 5% plastic-container products. Paragraph IV challenges are unlikely to be a central issue because there is no major branded reference product with a valuable unexpired patent estate.
Potential litigation would more likely involve:
- Manufacturing-process rights.
- Packaging or container patents.
- ANDA approval disputes.
- Product-liability claims.
- Supply, licensing, or distribution agreements.
- Alleged infringement involving a narrow formulation patent.
The absence of a meaningful litigation record reduces legal delay risk but also confirms that the product has limited defensible differentiation.
Are there licensing deals for this product?
No major publicly disclosed licensing transaction appears to define the commercial market for theophylline in 5% dextrose plastic containers. Products in this category are more likely to move through generic asset transfers, contract manufacturing arrangements, wholesaler agreements, or portfolio acquisitions than through high-value branded licensing deals.
A licensee would generally obtain value from:
- An approved injectable dossier.
- An established sterile manufacturing site.
- Hospital contracts.
- Drug-shortage positioning.
- A transferable NDC and distribution network.
The commercial value of such an arrangement would depend on supply continuity and manufacturing cost rather than patent rights.
How does this product compare with aminophylline injection?
| Attribute |
Theophylline in Dextrose 5% |
Aminophylline injection |
| Active form |
Theophylline |
Theophylline-ethylenediamine complex |
| Administration |
IV infusion in dextrose vehicle |
Typically IV injection or infusion |
| Dosing complexity |
High |
High |
| Therapeutic window |
Narrow |
Narrow |
| Monitoring need |
Significant |
Significant |
| Generic competition |
High |
High |
| Patent position |
Expired or immaterial |
Expired or immaterial |
| Clinical trend |
Declining |
Declining |
| Main commercial risk |
Formulary substitution and discontinuation |
Same, with added product-specific supply variation |
The products are clinically related but are not automatically interchangeable. Prescribing information and institutional protocols determine the appropriate product and dose.
Key Takeaways
- Theophylline and Dextrose 5% in a plastic container is a mature, off-patent intravenous generic product.
- No meaningful active-ingredient exclusivity remains.
- No product-specific clinical-trial program supports a new indication or market expansion.
- The principal competitors are other generic theophylline or aminophylline products and modern inhaled or systemic respiratory therapies.
- Public sources do not separately report a reliable market size for this exact container presentation.
- The market outlook is flat to declining, with temporary upside possible during competitor withdrawals or shortages.
- Sterile manufacturing, container compatibility, regulatory compliance, and hospital contracting matter more than patents.
- Paragraph IV challenges and patent litigation are not central commercial risks.
- Long-term revenue potential is limited without a broader hospital-injectable portfolio or a supply-constrained market.
FAQs
Is Theophylline and Dextrose 5% the same as aminophylline?
No. Theophylline is the active compound in the product, while aminophylline is a theophylline-ethylenediamine complex. Dosing and administration should follow the specific product label.
Does the product have biosimilar competition?
No. Biosimilars apply to biological products. Theophylline is a small-molecule drug and is subject to generic-drug competition instead.
Can a hospital substitute nebulized albuterol for intravenous theophylline?
Clinical substitution depends on disease severity, patient response, contraindications, and institutional protocol. Albuterol and theophylline are different products with different routes, pharmacology, and monitoring requirements.
Is the plastic container itself patentable?
A plastic infusion container or container system can be patentable, but any such right would be separate from the expired theophylline molecule and would need to remain unexpired and broad enough to cover the marketed configuration.
What is the main investment risk for a manufacturer?
The main risk is insufficient volume to support sterile manufacturing and distribution costs. Demand erosion, hospital formulary substitution, competitor pricing, and product discontinuation are more material than branded patent expiry.
References
-
National Library of Medicine. (n.d.). ClinicalTrials.gov: Theophylline clinical studies. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Theophylline injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.-c). National Drug Code Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
-
Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. https://ginasthma.org/
-
Global Initiative for Chronic Obstructive Lung Disease. (2024). Global strategy for the prevention, diagnosis and management of COPD. https://goldcopd.org/
